Background
==========

Managing SpO~2~ to a target range rather than just increasing FiO~2~ in response to an episode of desaturation became the standard of care more than a decade ago. Subsequently, shifting of SpO~2~ target ranges was shown to have important impact on outcomes \[[@B1]-[@B3]\]. Most importantly, recent large multicenter trials have shown that pulmonary and retinal morbidity can be reduced, by lowering the SpO~2~ target range, but also that lowering it too low, increases mortality \[[@B4]-[@B7]\]. It was reported some time ago that lower SpO~2~ target ranges are also associated with an increased rate of desaturations \[[@B8]\]. It has been recently speculated that this effect might explain the increased mortality seen in trials of lower target ranges \[[@B9]\].

Clinically applying the results of this targeting evidence is challenging because of the difference between the SpO~2~ target range specified and the SpO~2~ exposure actually achieved. Furthermore selecting the optimal clinical SpO~2~ target range is additionally complicated by the realities of manual titration of FiO~2~ in the busy newborn ICU \[[@B10]-[@B12]\]. That is, the selection of the clinical SpO~2~ target range must take into account what is practical.

Automated closed loop control systems have been proposed, studied and shown to be effective \[[@B13]-[@B16]\]. One is commercially available, and has been in routine use in our units for two years. (AVEA-CLiO2, CareFusion, Yorba Linda CA, USA). Such systems can make adjustments to FiO~2~ as often as every second. This is in contrast to nurses responding to persistent alarms and making adjustments, generally within minutes. Automation of SpO~2~-FiO~2~ control, because it does not require constant nursing intervention, also makes it practical to consider different paradigms for management of SpO~2~ exposure.

Our aim was to compare, using a crossover design, the relative effectiveness of our automated SpO~2~-FiO~2~ system set at two difference control ranges. The first was our standard SpO~2~ target range of 87-93% and the second, a narrower range with a higher midpoint (90-93%). The former was selected with the idea that lower SpO~2~ associated with the increased risk of desaturations might be reduced.

Methods
=======

The study was conducted in two tertiary care neonatal centers in Poland (The Medical Center of Postgraduate Education, Warsaw and City Hospital, Ruda Slaska).

Our research was approved by the The Ethics Committee of the Medical Centre of Postgraduate Education. Written informed consent was obtained from the parents of each patients.

In this study we use the term set control range to describe the settings on the automated SpO~2~-FiO~2~ control system and the term target range to describe the desired clinical target range for SpO~2~. The study was a crossover design, where subjects were switched between the two set control ranges, every 12 hours for 3 days. One range was that used routinely in the unit (87-93% SpO~2~) the other was 90-93% SpO~2~. To avoid the concern that different levels of nursing staffing and frequency of procedures in the evenings might effect the relative oxygenation stability, the change was made midday. The order was randomized for each day. For analysis, each subject's experience over the study at each set control range was averaged together. Digital SpO~2~ and FiO~2~ data were collected every 5 seconds from the ventilator. Infants were enrolled if the research staff and data collection system were available, if they had exhibited at least 4 desaturations \<80% SpO~2~ in the preceding 8 hours, and if they were expected to remain on their current mode of respiratory support (invasive or noninvasive) for the 3-day study period.

The prospectively selected primary endpoints were % time in our standard 87-93% SpO~2~ target range, % time at SpO~2~ extremes (SpO~2~ \< 80% or \>98%) and the % time with SpO~2~ between 80-86%. Time when SpO~2~ was over the SpO~2~ target range, but the FiO~2~ was 0.21, was included in the time in SpO~2~ target range. We hypothesized that the narrower SpO~2~ range would result in more time in the 87-93% SpO~2~ range, comparable time at SpO~2~ extremes and less time with SpO~2~ between 80%-86%. Based on data from a pilot study, we projected a sample size of 20 subjects would be able to detect a 3% difference in the time in the target range and low SpO~2~ range (power \>90%, p \< 0.05) and also a 1% difference in the SpO~2~ extremes (power \>80%, p \< 0.05).

All the primary and descriptive endpoints were continuous variables. Evaluation of the paired differences between the two set control ranges were tested with the Andersen-Darling test for normality. When a normal distribution was not present, a Wilcoxon Signed Rank Test was used to evaluate paired differences. Otherwise two tailed paired t-tests were used. A p \< 0.05 was considered statistically significant for all comparisons. A post hoc evaluation of the relationship between % time in the target range and rate of severe desaturations was explored with linear regression and correlation. All the statistical tests were conducted with SigmaXL version 6.1 (Toronto, Canada).

Results
=======

The study was conducted between November 2011 and February 2013. Twenty-four infants were enrolled. Three experienced clinical changes unrelated to the study and did not complete more than 1 day of study. They were excluded. Eighteen completed 3 days and 3 completed 2 days. Of these 21 infants, 8 were intubated, 6 received nasal positive pressure ventilation and 7 nasal continuous airway pressure. The baseline characteristics \[median(IQR)\] of the subjects were, EGA: 27 weeks (26--29), study weight: 1.08 kg (0.86-3.65), age: 17 days (1--26) and FiO~2~: 0.32 (0.24-0.90).

During the study period a significant desaturation (SpO~2~ \< 80%) occurred about every 30 minutes. Among the subjects, the incidence of these significant desaturations ranged between every 120 minutes and every 10 minutes. The need to manually adjust FiO2 was uncommon (\<2 per day). The histogram of the SpO~2~ exposure for the two control settings is seen in Figure [1](#F1){ref-type="fig"}. There is a clear difference. The mean of the SpO2 medians during 90-93% control, which also had a higher midpoint, was correspondingly higher than the median for the standard 87-93% SpO~2~ control range (91.9% vs 90.7% p \< 0.001). The interval of the IQR of SpO~2~ associated with the 90-93% control range was narrower (3.0% vs 4.3% p \< 0.001).

![**Histogram of SpO2 exposure for the two Control Ranges.** The bar highlights the standard target range (87-93% SpO~2~).](1471-2431-14-130-1){#F1}

The primary endpoints are tabulated in the Table [1](#T1){ref-type="table"}. Times in the 87-93% SpO~2~ target range, and at SpO~2~ extremes were clinically comparable, and not statistically significantly different. However there was a trend suggesting less time with SpO~2~ \< 80% during 87-93% control. The median time with SpO~2~ between 80-86% was statistically significantly less (6.2% vs 8.4%, p = 0.006) during periods when the control range was set at 90%-93%. However, as is suggested in Figure [1](#F1){ref-type="fig"}, the higher narrower set range resulted in more time with SpO~2~ between 94-98% (16.4% vs 12.0%, p = 0.005).

###### 

The primary endpoints

                                **87-93**         **90-93**      **p**
  ------------------------- ----------------- ----------------- -------
  Time\* in 93-87% SpO~2~     72.9% (16.8)      71.3% (16.4)     0.813
  Time \<80% SpO~2~          1.6% (3.4-0.7)    1.7% (3.1-0.5)    0.052
  Time\* \>98% SpO~2~        0.4% (0.7-0.1)    0.4% (1.9-0.2)    0.102
  Time 86-80% SpO~2~         8.4% (11.4-6.8)   6.2% (10.3-2.8)   0.006

Data mean(stdev) or median(IQR). p from paired Wilcoxon Sign Rank test for medians and paired t-test for means, \*% Time \>93% when FiO~2~ = 0.21 is treated as in 87-93%.

There were no clinically relevant differences between the two set control ranges (90-93%, 87-93%) in the median frequency of desaturations \<80% SpO~2~ (1.7/hour vs. 1.9/hour, p = 0.25), or the median duration of those episodes \<80% SpO~2~ (16.4 seconds vs. 14.8 seconds, p = 0.57).

The percent time with SpO~2~ between 87-93% for these subjects varied widely (34% to 94%). Time in this target range was highly correlated (R squared = 0.720) to the frequency of desaturations \<80% and decreased 2.4% with every added desaturation/hour. This relationship was nearly identical for the two control ranges.

Discussion
==========

We compared the relative effectiveness of automated control of SpO~2~-FiO~2~ set at two control ranges. One range reflected our clinical practice at the time (87-93% SpO2) for both manual and the automated SpO~2~-FiO~2~ system control. The second was narrower with a higher midpoint (90-93% SpO~2~). We found that both set control ranges were effective, but that there were differences. The narrower range did not increase time in the intended target range (87--93 SpO~2~) or markedly impact time at SpO~2~ extremes (\<80%, \>98%). The narrow range, with a higher midpoint, did result in less time with lower SpO~2~ (80-86%), more time with higher SpO~2~ (94-98%) and also a tighter distribution of the SpO~2~.

This is, we believe, the first report of a comparison of the relative effectiveness of two automated control ranges. We suggest that our study demonstrates the potential to use automated control ranges that are narrower or shifted to impact changes in SpO~2~ exposure. In this study we were able to reduce the time below the desired SpO~2~ target range, provide tighter control, but not increase time in the SpO~2~ target range. The latter was a result of more time above the target range. We have since participated in a large multicenter study that was completed in early 2014 \[[@B17]\]. This multicenter study is not only comparing two narrow target ranges, but also the relative effectiveness of automated SpO~2~-FiO~2~ system and manual control for the two ranges. We hope that the results of this new study, when considered with our findings, will result in better insight into optimum automated targeting strategies.

Claure validated the relative effectiveness of CLiO2 as compared to manual control in two studies \[[@B13],[@B14]\]. In both these studies automated SpO~2~-FiO~2~ system control resulted in more time in the designated SpO~2~ target range and less time with SpO~2~ \> 98%, as compared to manual control. However, both of these studies also showed that automated SpO~2~-FiO~2~ control was associated with more time below the target range. We speculated that this effect was a result of a shift in distribution related to the higher median SpO~2~ experienced during manual control. In our study a shift in the median SpO~2~ between the two set control ranges also resulted in a reduction in the time with SpO~2~ between 80-86%. In our study the range with a higher median SpO~2~ also was narrower and resulted in a tighter distribution. The latter would also have reduced the time between 80%-86% SpO~2~. It is not possible, therefore, to determine from our data to what degree these two factors were causal. However we speculate that a narrower control range with the same mid point as the desired target range would result in optimum results.

McEvoy demonstrated in 21 intubated infants with chronic lung disease that a lower level of baseline SpO~2~ control resulted in a tripling of the incidence of significant desaurations \[[@B8]\]. In evaluating the evidence of increased mortality associated with lower SpO~2~ target range, it has been speculated that this effect might be the cause of increased mortality in infants managed with a low target range \[[@B9]\]. In our study we found no difference between the rate of severe desaturations associated between the two assigned ranges. In our study, while both control ranges had similar time in the desired SpO~2~ target range, the 90-93% range resulted in a higher median SpO~2~, and less time below the SpO~2~ target range and 80% SpO~2~. In McEvoy's study there was a much more marked difference in both the median SpO~2~ and time below the SpO~2~ target range. We feel this bigger difference likely explains the difference between our results. We further suggest that the ability of automated SpO~2~-FiO~2~ control to reduce the time below the SpO~2~ target range, might reduce the risk of this problem as seen in McEvoy's study and other studies of SpO~2~ targeting.

In a previous crossover study we compared CLiO2 with two difference manual control strategies in 15 infants during 8-hour test periods \[[@B18]\]. We found that the relative effectiveness of automated control was much more pronounced in infants experiencing frequent severe desaturations. For this reason, on a post hoc basis, we explored the effect of desaturation rate and time in the SpO~2~ target range. We found a linear relationship of decreasing time in the SpO~2~ target range to increasing rate of severe desaturations, which is consistence to the effect seen in our previous study.

While offering great promise for increased effectiveness, automation of FiO~2~ control also dramatically reduces the need for nursing intervention, with significant potential for labor savings. We reported that manual adjustments of FiO~2~ occurred less than twice per day. In a multicenter trial, Claure reported 10 FiO~2~ adjustments per day during automated control, a decrease of over 90% compared to manual control \[[@B14]\]. In contrast Hallenberger, from the multicenter comparison of a different FiO~2~-SpO~2~ control system, reported that FiO~2~ adjustments were made 52 times per day during automated control, a decrease of 32% compared to manual control \[[@B15]\]. Both studies reported a wide variation among patients, as was also the case in our study. The system studied by Hallenberger has implemented a different approach to FiO~2~ control, that would by its nature require more nursing intervention. The difference between our experience of less than 2 per 24 hours and that reported by Claure is primarily a result of the stability of the infants being studied, we believe. That is, there was a wide difference in the FiO~2~ level, the rate of severe desaturations and time in the target range between the study populations. This is only a speculation, as factors such as the SpO~2~ alarm settings and general attentiveness of the staff might also be related.

Our study has some limitations. It was a relatively small study of 21 infants. Still it represents almost 1500 hours of automated control, nearly twice that reported in the largest prior study of CLiO2 \[[@B14]\]. In addition we saw a trend toward more time \<80% SpO~2~ in one intervention, a larger sample with more power would have clarified the relevance of this trend. The study population was also diverse in terms of frequency of severe desaturations, weight and mode of respiratory support. We feel that this is an advantage as it reflects the typical intended population for use. However the study was not powered to explore relative differences in among these categories. Finally we studied an SpO~2~ range that was both narrower and higher, confounding the interpretation of the effect of these two parameters.

Conclusions
===========

We found that a shift in the median of the set control range of CLiO2 had a proportional effect on the median and distribution of SpO~2~ exposure. We found that a dramatic narrowing of the set control range, had a disproportionally smaller impact. Our study points to the potential to optimize SpO~2~ targeting with an automated FiO2-SpO2 control system.
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